OTC Markets Group Welcomes Newly Verified OTCQB Companies – Jan. 6

OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced the following companies are verified for trading on OTCQB®, the venture marketplace for entrepreneurial and development stage companies, effective January 6, 2015: 

AmbiCom Holdings, Inc. (OTCQB: ABHI) – AmbiCom delivers its medical device OEM modules to many global medical device companies, including Cardinal Health/Carefusion, Siemens, Draeger and Roche.

AmbiCom is approved to continue trading on OTCQB.

HCi VioCare (OTCQB: VICA) – HCi VioCare is aiming at creating the first state-of-the-art chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe, with global reach, with a holistic approach regarding rehabilitation services to the physically impaired.  The company is operating under the strict British standards and will be certified by the International Society of P&O.  

HCi VioCare is approved to continue trading on OTCQB.

OncoSec Medical Incorporated (OTCQB: ONCS) – OncoSec Medical is a biopharmaceutical company developing its proprietary DNA-based intratumoral cancer immunotherapy technology, ImmunoPulse.  OncoSec Medical's core technology is designed to enhance the local delivery and uptake of DNA IL-12 and other DNA-based agents that target tumor-induced immune subversion pathways.  ImmunoPulse is a therapeutic approach that utilizes an electroporation delivery device in combination with DNA-encoded immune target modulators to treat cancer. Clinical studies of ImmunoPulse have demonstrated that the therapy is well-tolerated and preliminary evidence of anti-tumor activity has been observed, including the potential to initiate an immune response without the toxicities associated with systemic treatments.  OncoSec Medical's lead program is evaluating ImmunoPulse for the treatment of metastatic melanoma.  A Phase 2b study is in development to evaluate ImmunoPulse in combination with a checkpoint inhibitor, called anti-PD1 (pembrolizumab), for the treatment of metastatic melanoma and is being conducted in collaboration with several prominent academic medical centers.  The company is also focused on identifying and developing new DNA-encoded proteins that target key pathways of tumor-induced immune subversion, investigating additional tumor indications, and evaluating other combination-based immunotherapy approaches.

OncoSec Medical upgraded to OTCQB from the OTC Pink® marketplace.

U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for these companies on www.otcmarkets.com. 

About OTC Markets Group Inc.

OTC Markets Group Inc. (OTCQX: OTCM) operates Open, Transparent and Connected financial marketplaces for 10,000 U.S. and global securities.  Through our OTC Link® ATS, we directly link a diverse network of broker-dealers that provide liquidity and execution services for a wide spectrum of securities.  We organize these securities into marketplaces to better inform investors of opportunities and risks – OTCQX®, The Best Marketplace; OTCQB®, The Venture Marketplace; and OTC Pink®, The Open Marketplace.  Our data-driven platform enables investors to easily trade through the broker of their choice at the best possible price and empowers a broad range of companies to improve the quality and availability of information for their investors.  To learn more about how we create better informed and more efficient financial marketplaces, visit www.otcmarkets.com.

OTC Link ATS is operated by OTC Link LLC, member FINRA/SIPC and SEC regulated ATS. 

Subscribe to the OTC Markets RSS Feed 

Media Contact:

Saskia Sidenfaden, OTC Markets Group Inc., +1 (212) 896-4428, saskia@otcmarkets.com